Invega
(Paliperidone)ApprovedSmall molecule
Paliperidone is used to treat schizophrenia and schizoaffective disorder, which are mental health conditions that affect how a person thinks, feels, and behaves. It helps reduce symptoms like hallucinations, delusions, and disorganized thinking.[2] Invega is currently approved and in use across 7 indications[4].[1]
Invega is one of 155 small molecule programs targeting Bipolar Disorder. It is currently in Approved.
7
Indications
92
Total Trials
4
Active Trials
154
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
174 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Invega
WWim Janssens
Approved
Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Inapsine
Jazz PharmaceuticalsPreclinical
Depakote
AbbViePreclinical
Ibrance
PfizerPreclinical
Lunesta
Akero TherapeuticsPreclinical
Luvox
SSolvay Pharmaceuticals
Preclinical
Catapres
Boehringer IngelheimPreclinical
Rapamune
PPrism Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Schizophrenia60 trials
Show 57 more trials
Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study
Not yet recruiting·—·Phase 4·NCT07153835·505 enrolled
Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia
Completed·
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00589914·1,221 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00589914·1,221 enrolledIntramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00073320·88 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00073320·88 enrolled
Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00101634·518 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00101634·518 enrolledLong-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia
Completed·—·N/A·NCT02918825·100 enrolled
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
Unknown status·CConsorcio Centro de Investigación Biomédica en Red (CIBER)·Phase 4·NCT06060886·244 enrolled
Antipsychotics4 trials
Bipolar Disorder3 trials
Psychosis2 trials
19 more indications
Effectiveness2 trials
Treatment2 trials
Aripiprazole1 trial
Bipolar I Disorder1 trial
ALS1 trial
A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00791349·141 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00791349·141 enrolledObsessive-Compulsive Disorder1 trial
Long-Acting Injection1 trial
Cognitive impairment1 trial
Suicidality1 trial
Oral1 trial
Schizoaffective Disorder1 trial
Post-Traumatic Stress Disorder, PTSD1 trial
Efficacy and Safety1 trial
A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00668837·407 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00668837·407 enrolledMethamphetamine Dependence1 trial
Medication1 trial
Magnetic Resonance Imaging1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Aug 26, 2008
INVEGA
NDA NDA021999
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Invega drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Paliperidone. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Serotonin 2a (5-Ht2a) Receptor Antagonist; Dopamine D2 Receptor Antagonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- WWim Janssens